2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Nasdaq stocks posting largest percentage decreases
AP - Fri May 09, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
After Yesterday's Decline of 13.72%, Keryx Biopharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu May 08, 5:14PM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) traded in a range yesterday that spanned from a low of $12.11 to a high of $13.19. Yesterday, the shares fell 13.7%, which took the trading range below the 3-day low of $13.99 on volume of 8.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why Keryx Biopharmaceuticals (KERX) Stock Is Down Today
at The Street - Thu May 08, 2:42PM CDT
Keryx Biopharmaceuticals (KERX) is down double digits after losing more money this quarter than it had during the same period last year.
Why Keryx Biopharmaceuticals, Inc. Shares Swooned
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 12:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Keryx Biopharmaceuticals , a...
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 6:08AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease (the "Company"
Pre-market Biotech Picks -- Research on Dendreon, Keryx Biopharma, Idera Pharma, and Vertex Pharma
PR Newswire - Wed May 07, 7:00AM CDT
The US markets saw a negative sentiment on Tuesday, May 6, 2014, with the NASDAQ Composite closing at 4,080.76, down 1.38%, the Dow Jones Industrial Average ending the session 0.78% lower at 16,401.02, and the S&P 500 edging 0.90% lower to finish the trading session at 1,867.72. The loss were broad based with nine out of the ten sectors finishing lower. The S&P 500 Health Care Sector Index ended the day at 666.48, down 0.91%, whereas the index has gained 4.08% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on DNDN, KERX, IDRA and VRTX can be downloaded upon signing up at:
Keryx Biopharmaceuticals Announces Opening of Boston Office
GlobeNewswire - Tue May 06, 9:16AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, is proud to announce the opening of its office in Boston, Massachusetts. A significant portion of the operations being built by Keryx to support the potential launch of Zerenex in the United States, including commercial, regulatory, medical affairs, legal, public affairs and pharamacovigilance, will be based in Boston.
Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2014 Financial Results
GlobeNewswire - Mon May 05, 3:40PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, today announced that a conference call will be held on Thursday, May 8, 2014 at 8:00 a.m. EDT to discuss results for the first quarter of 2014 and provide an update on the business.
3 Biotech Stocks With Upcoming Catalysts
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks are a sucker for a good catalyst. And they don't care what the overall market is doing when it arrives. Share prices can move north or south in a hurry, with little concern for larger market trends. So it's no wonder that investors...
Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and Legal
Thomson Reuters ONE - Tue Apr 15, 7:31AM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Keryx Biopharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.40%
Comtex SmarTrend(R) - Mon Apr 14, 5:35PM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) traded in a range yesterday that spanned from a low of $13.76 to a high of $15.07. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $13.90 on volume of 3.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Shares of KERX Up 69.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 11, 9:51AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 12 months, Keryx Biopharmaceuticals has returned 69.82% as of today's recent price of $14.46.